Table 1.
Distribution of α2c and β1 adrenergic receptor (AR) variants in controls and patients with heart failure
| Allele | ||||||
|---|---|---|---|---|---|---|
| Alleles and subjects | Frequency | P-value | Frequency | Genotype | P-value | |
| α2cDel322–325 | WT/WT | WT/Del | Del/Del | |||
| Controls | 0.11 | 0.011 | 95/119 (79.8%) | 23/119 (19.3%) | 1/119 (0.8%) | 0.022 |
| Patients with heart failure | 0.04 | 84/91 (92.3%) | 7/91 (7.7%) | 0/91 (0%) | ||
| β1Arg389 | Gly/Gly | Gly/Arg | Arg/Arg | |||
| Controls | 0.81 | 0.82 | 5/119 (4.2%) | 35/119 (29.4%) | 79/ 119 (66.4%) | 0.94 |
| Patients with heart failure | 0.80 | 5/91 (5.5%) | 26/91 (28.6%) | 60/91 (65.9%) | ||
| β1Ser49 | Gly/Gly | Gly/Ser | Ser/ Ser | |||
| Controls | 0.84 | 0.90 | 3/119 (2.5%) | 33/119 (27.7%) | 83/119 (69.7%) | 0.58 |
| Patients with heart failure | 0.84 | 4/91 (4.4%) | 21/91 (23.1%) | 66/91 (72.5%) | ||
P-values for comparisons of allele frequency or genotype frequency between controls and patients with heart failure were determined by 2 × 2 χ2 or by 2 × 3 exact probability test, respectively. P-value < 0.017 (0.05/3) was considered to be significant.